Promising Efficacy of M1-c6v1 Oncolytic Virus in Advanced Hepatocellular Carcinoma

Strategic Insights -

Research conducted at the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou, People's Republic of China, has demonstrated the safety and efficacy of combining M1-c6v1 oncolytic virus with camrelizumab and apatinib in patients with advanced hepatocellular carcinoma (HCC). The study, which enrolled 13 patients, showed a 70% overall response rate, with seven partial responses according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). The median overall survival and progression-free survival were 15.4 and 8.9 months, respectively.

Key Takeaways:

  • The treatment was well tolerated, with 92.15% of adverse events being grade 1 or 2.
  • The most common adverse events included influenza-like symptoms and transient cytopenia.
  • No viral shedding was detected in all secretions and excretions collected from subjects.
  • The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.
  • The study enrolled 13 patients, with 84.6% having hepatitis B virus-related HCC and 76.9% presenting with tumors 10 cm.
  • The treatment continued for up to 1 year or until disease progression, intolerability, or withdrawal.
  • Primary endpoints were safety and tolerability, and secondary endpoints assessed efficacy based on tumor response, progression-free survival, and overall survival.

Statistics:

  • 13 patients were enrolled in the study.
  • 84.6% of patients had hepatitis B virus-related HCC.
  • 76.9% of patients presented with tumors 10 cm.
  • The overall response rate was 70% (7/10).
  • The median overall survival was 15.4 months.
  • The median progression-free survival was 8.9 months.
  • 92.15% of adverse events were grade 1 or 2.

Sources:

  • Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2025;31(20):4288-4298.
  • NewsRx. Studies Conducted at Third Affiliated Hospital of Sun Yat-Sen University on Cancer Gene Therapy Recently Reported (Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma). Clinical Trials Week. October 27, 2025; p 73.